Wolverine Legal Status, FDA 503A Category, and Compounding Access

Access is under active FDA review

The Wolverine legal status story is, right now, a story of momentum. Access to compounded BPC-157 and TB-500 is under active FDA review and may expand in 2026: the FDA Pharmacy Compounding Advisory Committee (PCAC) has a meeting scheduled for July 23-24, 2026 to discuss these peptides as candidates for the section 503A bulks list [P3]. That meeting is the anchor fact, and it is a forward-leaning one — these substances are formally on the table.

But a PCAC discussion is an advisory step in FDA's evaluation, not a final listing decision, and no outcome should be assumed [P3]. So the honest framing is hedged: the direction of travel is toward review and possible expansion of compounding access; the destination is undecided. Everything below states present-tense facts, cites FDA, and treats the July 2026 meeting only as a scheduled discussion — never as a reclassification, a date-certain change, or a foregone conclusion. This page is general information about the regulatory landscape, not legal or medical advice, and not an offer to sell or supply any substance.

The present-tense fact: both components are 503A Category 2

As of today, both of Wolverine's components are research peptides that FDA has placed in 503A "Category 2." Under the Federal Food, Drug, and Cosmetic Act, drug compounding is governed by two sections: 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians pursuant to a prescription for an individual patient, and 503B covers FDA-registered outsourcing facilities compounding larger batches under FDA oversight [P1]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [P1].

Category 2 is FDA's designation for nominated bulk substances that FDA has identified as raising significant safety risks. Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1 — FDA has stated it would consider taking action against a compounder for compounding with a Category 2 substance [P1]. FDA placed both BPC-157 and the Thymosin Beta-4 fragment (LKKTETQ, also known as TB-500) in Category 2, effective with the September 29, 2023 update to the nominated-substances list, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [P2]. As a present-tense matter, compounding-pharmacy access to these peptides is therefore restricted.

Both BPC-157 and TB-500 are on the July 2026 PCAC agenda

There is no component carve-out within the blend. Both of Wolverine's constituents are currently Category 2, and both are under the same scheduled review. FDA's public advisory-committee calendar lists BPC-157 ("BPC-157 (free base)" / "BPC-157 acetate") and TB-500 ("TB-500 (free base)" / "TB-500 acetate") on the agenda of the Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026, as bulk drug substances "being considered for inclusion on the 503A Bulks List" [P3].

That is the precise, citable status: both peptides are under evaluation, discussed at one scheduled meeting, not yet on the final bulks list and not removed from Category 2. The listing on the agenda is consistent with the evaluation being ongoing rather than resolved [P3]. We do not state any reclassification as already done, dated, or certain, and we do not attach an outcome to the July 2026 meeting.

How legally compounded peptide access works

In general terms, a legally compounded medication in the United States is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [P4]. The preparation is then made either by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger or office-use volumes, sourced from an FDA-registered 503B outsourcing facility [P4].

Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued, but it does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate prescriber-patient relationship and a valid prescription [P4]. The ingredient-eligibility caveat is the binding constraint here: a compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules. An ingredient FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands — which is exactly where BPC-157 and TB-500 are today [P4][P1]. None of this is medical or legal advice; it is a general description of how the lawful pathway is structured.

Legal-status questions, answered from the FDA record

The three questions below are answered strictly from the audited FDA reference, in the present tense, with no assumed future outcome.